United States securities and exchange commission logo

                              October 20, 2020

       Omid Farokhzad, M.D.
       Chief Executive Officer
       Seer, Inc.
       3800 Bridge Parkway, Suite 102
       Redwood City, California 94065

                                                        Re: Seer, Inc.
                                                            Draft Registration
Statement on Form S-1
                                                            Filed September 25,
                                                            CIK No. 0001726445

       Dear Dr. Farokhzad:

              We have reviewed your draft registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional

       Draft Registration Statement Submitted September 25, 2020

       Cover Page

   1.                                                   We note that each share
of Class B common stock is entitled to ten votes per share. Please
                                                        tell us whether you
will be considered a controlled company and if so, please include
                                                        disclosure of your
controlled company status on the prospectus cover page and, if true,
                                                        that you do not intend
to comply with certain corporate governance requirements.
       Overview, page 1

   2.                                                   We note the comparison
of your Proteograph product to the success of next generation
                                                        sequencing technologies
in the field of genomics. Please revise to balance the disclosure
                                                        to indicate that there
can be no guarantee that your products will achieve similar results.
 Omid Farokhzad, M.D.
Seer, Inc. LastNameOmid Farokhzad, M.D.
October  20,NameSeer,
             2020     Inc.
Page  2 20, 2020 Page 2
FirstName LastName
3.       We note you have a three phase plan to commercialize your product.
Please tell us
         whether you plan to charge customers for your products with whom you
collaborate in the
         first phase of commercialization and whether you anticipate any sales
discounts or other
         promotions in connection with the second or third phases of your
         plans. Please also quantify the size of your installed base.
4.       Please revise to disclose clearly and prominently that your products
are currently labeled
         for research use only. Also revise to disclose how this designation
impacts your
         addressable market.
Markets, page 6

5.       We note that you provide the overall market size for the proteomics
and genomics
         markets. Please disclose the portion of these markets that are
addressable by the potential
         applications of your Proteograph product. Please also clarify whether
you will need FDA
         approval for any other these potential applications, such as
Material Weakness, page 32

6.       Please disclose the details surrounding your conclusion that you lack
the necessary
         number of accounting personnel to remedy your internal control
weaknesses. Specifically,
         please disclose how many accounting personnel you hired in 2020 and
how many
         additional accounting personnel you believe are needed to remedy the
weaknesses -- and
         when you anticipate these additional personnel to be hired.
Use of Proceeds, page 62

7.       We note you intend to use the net proceeds from this offering to
support research and
         development, to commercialize your Proteograph Product Suite and for
general corporate
         purposes. Please disclose the approximate amount intended to be used
for each such
         purpose as required by Item 504 of Regulation S-K. Please also specify
how far in the
         commercialization process of the Proteograph product you expect to
reach with the
         proceeds of the offering. If any additional funds will be needed to
accomplish the goals
         listed, please discuss the sources and amounts of those additional
PrognomIQ, page 74

8.       Please expand your description of the transaction rationale to
specifically explain how the
         new application growth ecosystems are significantly greater at the
affiliated entity as
         opposed to having the development activities performed directly by the
Registrant. Given
         that the Registrant holds a significant equity interest in the
affiliated entity, please disclose
         the affiliate's planned business activities. For example, it is not
clear whether the affiliate
         has the facilities and personnel needed to perform substantive
research and development
         activities. Further, it is not clear whether the Registrant will be
providing facility space,
         personnel, and specific services on behalf of the affiliate.Disclose
also whether the
         Registrant has a contractual right to any fees or royalties related to
the PrognomIQ
 Omid Farokhzad, M.D.
Seer, Inc.
October 20, 2020
Page 3
         intellectual property transfers, licenses and assignments referenced
on page 118.
Stock-Based Compensation, page 79

9.       Please expand this disclosure to quantify the amount of compensation
expense that will be
         generated by the 2020 equity issuances referenced in Item 15. Disclose
also in MD&A the
         amount of stock compensation expense that you expect to recognize in
fiscal 2021 from
         all existing compensatory equity issuances.
Collaboration and License Agreements, page 117

10.      Please expand your discussion of the intellectual property transfer
and license agreement
         with PrognomIQ to include the material financial terms including
milestone payments and
         royalty terms. Please also file the agreement as an exhibit or tell us
why you are not
         required to do so. See Item 601(b)(10) of Regulation S-K.
Description of Capital Stock
Exclusive Forum, page 151

11.      Please revise this section so that it is consistent with the risk
factor disclosure on page 54
         where you state that that the federal district courts will be the
exclusive forum for
         resolving any complaint asserting a cause of action arising under the
Securities Act.
Financial Statements, page F-1

12.      Please revise your filing to include interim financial information
according to the
         guidance in Rule 3-12 of Regulation S-X.

13.      Please revise the Exhibit Index to clarify your basis for redacting
certain information
         contained in Exhibit 10.6. In this regard, we note that the notation
below your Exhibit
         Index indicates that you are requesting confidential treatment for
information contained in
         the exhibits. Please revise the Exhibit Index accordingly or advise.

14.    Please supplementally provide us with copies of all written
communications, as defined in
FirstName LastNameOmid Farokhzad, M.D.
       Rule 405 under the Securities Act, that you or anyone authorized to do
so on your behalf,
Comapany    NameSeer,
       present         Inc.investors in reliance on Section 5(d) of the
Securities Act, whether or
               to potential
        20,they retain
             2020 Pagecopies
                        3    of the communications.
FirstName LastName
 Omid Farokhzad, M.D.
Seer, Inc. LastNameOmid Farokhzad, M.D.
October  20,NameSeer,
             2020     Inc.
Page  4 20, 2020 Page 4
FirstName LastName
       You may contact Tracie Mariner at 202-551-3744 or Al Pavot at
202-551-3738 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Chris Edwards at 202-551-6761 or Celeste Murphy at 202-551-3257 with
any other


                                                         Division of
Corporation Finance
                                                         Office of Life
cc:      Christina L. Poulsen